Executive summary
Mexico's COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) regulates peptides under the Ley General de Salud (General Health Law). Approved peptide medicines require a sanitary registration. Compounding follows NOM-249-SSA1-2010 (with an updated draft PROY-NOM-249-SSA1-2025). Research-use-only peptide marketing may constitute unauthorized drug promotion or supply where human use is implied, depending on the product, claims and transaction facts.
Authorities and legal categories
COFEPRIS: sanitary registration, pharmacovigilance, enforcement, import control.
SSA (Secretaría de Salud): policy direction.
CIPAM (Comisión Interinstitucional para la Protección contra Riesgos Sanitarios): interagency coordination.
Key instruments:
Ley General de Salud (LGS).
Reglamento de Insumos para la Salud (RIS).
NOM-249-SSA1-2010 / PROY-NOM-249-SSA1-2025 — compounding standards.
Fracción Administered into a vein. Quelle der Definition: Neutral gloss; usage context: Routes, devices, and absorption primer · Glossar, Artículo 226 LGS — classification of substances.
| Checkpoint | COFEPRIS requirement described | Common mistaken inference | Source |
|---|---|---|---|
| Classification | Apply the General Health Law and product-specific intended-use evidence | A peptide or research label determines status by itself | General Health Law |
| Sanitary registration | Approved peptide medicines require a Mexican sanitary registration | FDA, EMA, or ingredient status automatically creates Mexican authorization | COFEPRIS register |
| Manufacture or compounding | Apply NOM-249-SSA1-2010 and the licensed-establishment/product-specific assessment; the 2025 text remains a draft | Mexico has a US section Sections of the US Food, Drug, and Cosmetic Act covering traditional compounding exemptions (503A) and outsourcing-facility compounding (503B). Under 503A, qualification conditions include a patient-specific prescription requirement; under 503B, conditions cover facility registration and bulk-substance eligibility. Quelle der Definition: United States regulation brief · Glossar-equivalent test or every research peptide is eligible for magistral preparation | Current COFEPRIS/DOF NOM record |
| Import | Registration must be held by the importer or foreign manufacturer's Mexican representative, subject to the exact route | The 2025 Equivalence Decree waives registration for unapproved products | Current COFEPRIS import and registration record |
| Sale and promotion | Consumer-facing promotion remains tied to authorized product status and claims | Social-media promotion or research wording falls outside medicine law | COFEPRIS authority records and the April 2026 alert |
- Classification, COFEPRIS sanitary registration, manufacture or compounding controls, import, and sale or promotion are distinct checkpoints.
- Reference-agency approval can feed evidence into COFEPRIS review but does not bypass it.
- Social-media claims can inform classification and intended use.
Approved medicines
Approved peptide medicines include Expansion of the abbreviation used in the monographs: glucagon-like peptide-1 receptor agonist. The atlas does not define the pharmacology of this class; see the monograph for what is documented about a specific compound. Quelle der Definition: Neutral gloss; the abbreviation is printed on the tirzepatide monograph but the atlas does not define the class pharmacology · Glossar (semaglutida/Ozempic, Wegovy; liraglutida/Victoza, Saxenda; tirzepatida/Mounjaro), insulin analogues, teriparatida (Forteo), leuprorelina, octreotida, desmopresina, and calcitonina.
Source: COFEPRIS sanitary register, https://www.gob.mx/cofepris
Compounding/manufacturing
NOM-249-SSA1-2010: governs sterile compounding in healthcare settings. Updated draft PROY-NOM-249-SSA1-2025 introduces stricter quality requirements.
The reviewed NOM-249 material does not establish a US-style section Sections of the US Food, Drug, and Cosmetic Act covering traditional compounding exemptions (503A) and outsourcing-facility compounding (503B). Under 503A, qualification conditions include a patient-specific prescription requirement; under 503B, conditions cover facility registration and bulk-substance eligibility. Quelle der Definition: United States regulation brief · Glossar “registered API / identified patient / essentially a copy” test. This page therefore does not declare a An entry with frequent visibility in the research-peptide ecosystem. Visibility is not endorsement, and marketed material is not assumed safe, sterile, authentic, or suitable for humans. Quelle der Definition: Scope and selection methodology · Glossar peptide eligible or ineligible for magistral preparation without an exact Mexican provision and a licensed- establishment/product-specific assessment.
Import
Import requires a sanitary registration held by the importer or the foreign manufacturer's Mexican legal representative.
Personal import: limited to approved medicines for personal use, with a prescription from a Mexican-licensed physician.
The June 11, 2025 Equivalence Decree simplified registration for medicines approved by reference agencies (FDA, EMA, etc.) but does not waive registration for unapproved peptide products.
Research-use-only products
COFEPRIS does not recognise a research-use-only exemption for products sold to consumers. In April 2026, COFEPRIS issued an alert specifically warning against social-media promotion of unapproved peptide products.
April 2026 alert: The cited COFEPRIS record concerns social-media promotion of unapproved peptide products. It is a dated, scoped warning, not a determination about every peptide product or every online post.
Enforcement examples and uncertainty
April 2026: COFEPRIS alert on social-media peptide product promotion.
2025: Equivalence Decree — semaglutide patent expiry analysis suggests potential for generic approvals, subject to biowaiver requirements.
Uncertainty: the scope of the magistral compounding exception for new peptide substances not in the pharmacopoeia remains untested.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: Latin America overview, Brazil, cross-border supply, and global framework.
Primary sources
COFEPRIS. https://www.gob.mx/cofepris
Ley General de Salud. https://www.diputados.gob.mx/LeyesBiblio/ref/lgs.htm
NOM-249-SSA1-2010 (searchable via COFEPRIS or DOF).
PROY-NOM-249-SSA1-2025 (searchable via COFEPRIS regulatory agenda).
COFEPRIS April 2026 Alert. https://www.gob.mx/cofepris (comunicados).